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Abstract
Purpose To determine the clinical impact of human leu-
kocyte antigen (HLA) class I expression in irradiated and
non-irradiated rectal carcinomas.
Experimental design Tumor samples in tissue micro array
format were collected from 1,135 patients. HLA class I
expression was assessed after immunohistochemical stain-
ing with two antibodies (HCA2 and HC10).
Results Tumors were split into two groups: (1) tumors
with >50% of tumor cells expressing HLA class I (high) and
(2) tumors with ·50% of tumor cells expressing HLA class
I (low). No diVerence in distribution or prognosis of HLA
class I expression was found between irradiated and non-
irradiated patients. Patients with low expression of HLA
class I (15% of all patients) showed an independent signiW-
cantly worse prognosis with regard to overall survival and
disease-free survival. HLA class I expression had no eVect
on cancer-speciWc survival or recurrence-free survival.
Conclusions Down-regulation of HLA class I in rectal
cancer is associated with poor prognosis. In contrast to our
results, previous reports on HLA class I expression in colo-
rectal cancer described a large population of patients with
HLA class I negative tumors, having a good prognosis.
This diVerence might be explained by the fact that a large
proportion of HLA negative colon tumors are microsatellite
instable (MSI). MSI tumors are associated with a better
prognosis than microsatellite stable (MSS). As rectal
tumors are mainly MSS, our results suggest that it is both,
oncogenic pathway and HLA class I expression, that dic-
tates patient’s prognosis in colorectal cancer. Therefore, to
prevent confounding in future prognostic analysis on the
impact of HLA expression in colorectal tumors, separate
analysis of MSI and MSS tumors should be performed.
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TME Total mesorectal excision
TNM Tumor node metastasis
Introduction
The immune system is thought to have an important func-
tion in controlling tumor growth and eliminating metasta-
sizing tumor cells. The expression of human leukocyte
antigen (HLA) class I, presenting tumor-associated anti-
gens on the tumor cell surface, is considered as a prerequi-
site for an eVective T cell immune response [34]. As a
consequence, tumor cells with down-regulated HLA class I
expression might escape this immune response, resulting in
a selective outgrowth of these tumor cells.
Many studies described HLA class I expression in cancer
[10, 17, 22, 33]. Only limited studies have reported on the
clinical impact of HLA class I expression in colorectal can-
cer with contrasting results. Some studies found no signiW-
cant correlation between staining intensity and survival [1,
19, 20], while others found a prognostic correlation between
HLA expression and survival [18, 35]. The latter two studies
had in common that total absence of HLA class I resulted in
a favorable prognosis as compared to patients with down-
regulated expression of HLA class I of tumor cells. The dis-
crepancy between these two studies is, whereas the one
described high expression of HLA class I in tumor cells that
resulted in a better prognosis as compared to the partial
down-regulation of HLA class I [35], the other found the
opposite [18]. These studies both analyzed a mixed popula-
tion of colon and rectal cancer patients. For rectal cancer
patients, the clinical impact of HLA class I expression is still
unknown. Since HLA class I expression is often absent in
microsatellite instable (MSI) tumors [9,  16] and MSI is
more frequently observed in right-sided colon tumors than
in rectal tumors [30], therefore the results obtained from a
mixed population of colon and rectal cancer patients might
not hold true for rectal cancer patients.
The purpose of this study was to analyze the clinical rel-
evance of HLA class I expression for rectal cancer patients.
In addition to determining the impact of MSI on HLA class
I expression, the tumors most at risk for MSI i.e. HLA-neg-
ative tumors were examined for MSI by determining the
expression of the mismatch repair proteins, mismatch mutL
homolog 1 (MLH1) and postmeiotic segregation increased
2 (PMS2), that are most absent in sporadic MSI tumors
[7,  36]. Radiotherapy has been described recently to
increase cell surface expression of major histocompatibility
complex (MHC) class I molecules in a murine colon adeno-
carcinoma cell line [26]. Therefore, our study also evalu-
ated the eVect of radiotherapy on HLA class I expression
in rectal cancer patients. For these purposes, HLA class I
expression was evaluated in a set of 1,135 formalin-Wxed
paraYn-embedded rectal cancer specimens. The tumors
studied were obtained at the time of surgery from patients
of a prospective multicenter trial, who were randomized
between standardized preoperative radiotherapy treatment
followed by surgery or surgery alone [15].
Materials and methods
Study population
Patients were obtained from the Dutch TME trial, a multi-
center trial that evaluated total mesorectal excision (TME)
surgery with or without preoperative radiotherapy (5 £ 5
Gray) [15]. Radiotherapeutical, surgical and pathological
procedures were standardized and quality-controlled [15,
21]. Tumor staging was determined using the tumor node
metastasis (TNM) classiWcation [29]. Patients with the
hereditary Lynch syndrome also known as hereditary non-
polyposis colorectal cancer (HNPCC) were excluded from
the TME trial. SuYcient formalin-Wxed paraYn-embedded
tumor material was available for 1,135 Dutch patients.
Three 2 mm cores of each tumor sample were arrayed into
tissue microarrays (TMA) as previously described [5].
Immunohistochemistry and microscopic analysis
TMAs [5] were immunohistochemically stained for HLA
class I using the mAb antibodies HCA2 and HC10
and the rabbit anti-2 m polyclonal Ab (A 072; DAKO
Cytomation, Glostrup, Denmark). The HCA2 and HC10
antibodies were applied in immunohistochemistry as
hybridoma culture supernatant, kindly provided by Prof.
J.J. Neefjes from the Netherlands Cancer Institute
(Amsterdam, The Netherlands). The reactivity spectrum
of HCA2 includes HLA-A (except HLA-A24), HLA-B73
and HLA-C molecules as well as HLA-E, HLA-F and
HLA-G antigens [27, 28, 31]. HC10 reacts with HLA-B
and HLA-C molecules and HLA-A10, -A28, -A29, -A30,
-A31, -A32 and -A33 heavy chains [13, 23, 31, 32]. The
immunohistochemical procedures are described in detail
elsewhere [18]. All tumor specimens were stained simul-
taneously to avoid intra-assay variation. Microscopic
analysis was assessed by two independent observers
(M.M. v. B. and M. v. V.) in a blinded manner. HCA2,
HC10 and 2 m stainings were scored in six categories.
Essentially, the scoring was divided into quartiles but for
tumors with less than 25% stained cells, there was a dis-
tinction made between those with 6–25% positively
stained tumor cells, those with approximately 1–5% posi-
tively stained cells and those with absolute no positively
stained tumor cells [3, 11]. Where discrepancies arose
between the staining of cores from the same tumor, anCancer Immunol Immunother (2008) 57:601–609  603
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average of the scores was taken, with conWrmation by
two observers using a double-headed microscope with a
consensus decision taken in all cases. Tissue stromal
cells, normal epithelium or lymph follicles served as pos-
itive internal controls to ascertain the quality of the stain-
ing. Patients were excluded if stromal cells of tumor were
not stained for HCA2 or HC10. Twenty-Wve tumors with
negative staining of the stromal cells for HCA2 were
excluded. HC10 showed in all tumors staining of the stro-
mal cells. Also TNM stage 0 patients, tumors lost due to
technical failure and ineligible patients were excluded,
leaving 1,092 tumors in which HC10, and 1,035 in which
HCA2 could be evaluated. Combining the results for
HCA2 and HC10 staining resulted in 1,008 eligible stage
I–IV rectal cancer patients for analyses of clinical impact
of HLA class I expression.
Tumors negatively stained for HCA2 and/or HC10 were
stained for mismatch repair proteins MLH1 and PMS2.
MLH1 and PMS2 are deWcient in sporadic MSI tumors.
Therefore, the expression of these proteins was used to
diVerentiate MSI and MSS rectal cancers. Tissue stromal
cells, normal epithelium or lymph follicles served as posi-
tive internal controls when analyzing MLH1, PMS2 expres-
sion. The expression of MLH1 and PMS2 was scored
positive if tumor cells showed expression, and negative if
tumor cells showed no expression of either MLH1 or
PMS2, provided that and tissue stromal cells did show
expression, indicating microsatellite stable (MSS) and micro-
satellite instable (MSI) tumors, respectively [7].
Statistical analyses
All analyses were performed with SPSS statistical software
(version 12.0 for Windows, SPSS Inc, Chicago, USA).
Mann–Whitney U, t test and 2-tests were used to compare
variables. Kaplan–Meier analyses were performed to ana-
lyze patient survival. The entry date for the survival analy-
ses was the time of surgery of the primary tumor. Events
for time to local recurrence, distant recurrence, cancer-spe-
ciWc survival, disease-free and overall survival were deW-
ned as follows: from time of surgery to time of local disease
relapse (for local recurrence), time of distant disease
relapse (for distant recurrence), time of disease relapse or
death by disease (for cancer speciWc survival), time of dis-
ease relapse or death (for disease free survival) and time of
death, respectively (for overall survival). Non-irradiated
and irradiated patients were Wrst separately analyzed in uni-
variate analysis and second, variables with a P value of
<0.10 in the univariate analyses were subjected to a multi-
variate analysis. Multivariate analysis was performed on
the whole group of irradiated and non-irradiated patients
with the following variables: HLA class I, randomization
for radiotherapy, TNM and circumferential margin. Cox’
regression analyses were used to calculate hazard ratios
(HR) with 95% conWdence intervals (CI).
Results
Scoring methods
Several methods are described to analyze HLA class I
expression in cancer. The standard is deWned by the Interna-
tional HLA and Immunogenetics Workshop (IHIW) [3, 11].
A recent paper describing HLA class I expression in colo-
rectal cancer used an adjusted form of this scoring method
[35]. Our scoring was primarily adapted from IWIH, i.e.
division into quartiles, but for tumors with less than 25%
stained cells a distinction was made between those with 6–
25% positive tumor cells, those with approximately 1–5%
positive tumor cells and those with absolute no HLA class I
positive-stained tumor cells. After scoring and analyzing
this method we found that patients in the groups with abso-
lute numbers, 1–5%, 6–25% and 26–50% HLA class I
expression of tumor cells did not diVer in prognosis but had
a worse prognosis as compared to patients with HLA class I
expression in groups with 50–75% and >75% of tumor cells
expressing HLA class I. Therefore, we distinguished two
categories. These two categories were (1) 0–50%; and (2)
>50–100% of tumor cells expressing HLA class I.
HCA-2 and HC10 staining in rectal cancer
Immunohistochemical staining with HCA2 and HC10 anti-
bodies demonstrated strong positive membrane staining
of stromal cells and tumor-inWltrating inXammatory cells,
indicating the success of the staining. A total of 1,035 and
1,092 tumors were evaluated with HCA2 and HC10; 324
(65%) irradiated tumors and 312 (58%) non-irradiated
tumors showed at least 50% of all tumor cells positive for
HCA2. Staining with HC10 resulted in 403 (76%) irradi-
ated tumors and 436 (77%) non-irradiated tumors that
showed more than 50% positive tumor cells. The complete
results are shown in Table 1. Representative examples of
the immunohistochemical stainings of tumors are displayed
in Fig. 1a–f. These results show that about 35% of irradi-
ated and 42% of non-irradiated patients showed less than
50% of the tumor cells expressing HCA2. HC10 is
expressed in less than 50% of the tumor cells in about 25%
of both irradiated and non-irradiated rectal cancer patients.
Analysis of HLA class I expression in rectal tumors
Together, the results obtained with HCA2 and HC10 are
expected to reXect HLA class I expression in rectal cancer. In
a group of 64 tumors it was studied whether an additional604 Cancer Immunol Immunother (2008) 57:601–609
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staining for 2 m would better deWne HLA class I expression.
The results of the addition of 2 m to HCA2 and HC10
were comparable to those obtained with HCA2 and
HC10, i.e. only 1 of 64 tumors was diVerently classiWed.
Therefore, 2 m was not scored in the whole cohort and
HLA class I expression was assessed by combining HCA2
and HC10.
A total of 406 (85%) irradiated and 445 (84%) non-
irradiated tumors exhibited expression of at least one of
the two markers showing >50% positive staining of all
tumor cells (further referred to as ‘the HLA class I high
expression group’). A total of 70 (15%) irradiated and 87
(16%) non-irradiated tumors showed reduced numbers
(·50%) of HLA class I positive tumor cells. Only 3
(0.6%) irradiated tumors and 8 (1.5%) non-irradiated
tumors showed total loss of HLA class I (negative for
both HCA2 and HC10). Survival results of patients with
total absence of HLA class I on tumor cells did not show
signiWcant diVerence from patients with reduced num-
bers of HLA class I positive tumor cells. Therefore, these
groups were combined and will be further referred to as
‘the HLA class I low-expression group’. The complete
results are shown in Table 2. The number of patients in
the group of the HLA class I high-expression group and
the HLA class I low-expression group was equally dis-
tributed between irradiated and non-irradiated tumors
Fig. 1 Examples of HCA2 and 
HC10 immunohistochemical 
staining of rectal tumors; 
a–c HCA2, d–f HC10 
expression. a, d Expression of 
HLA class I in >50% tumor 
cells; b, e expression of HLA 
class I in <50% tumor cells; 
c, f epithelial cells show total 
absence for HCA2 or HC10 and 
only stromal and inWltrative cells 
show positive staining for HCA2 
or HC10; Original magniWcation 
£20
Table 1 Most rectal tumors have high numbers of tumor cells positive
for HCA2 or HC10
Numbers (N) of patients are indicated with percentages shown in
parentheses, showing: expression of HCA2 and HC10 in more than
50% of the tumor cells (high), expression in less than 50% of the tumor
cells (low) and total absence (absence)
Irradiated 
patients N (%)
Non-irradiated 
patients N (%)
HCA2
High 324 (65%) 312 (58%)
Low 142 (28%) 174 (32%)
Absence 31 (6.2%) 52 (9.7%)
HC10
High 403 (76%) 436 (77%)
Low 117 (22%) 116 (21%)
Absence 8 (1.5%) 12 (2.1%)Cancer Immunol Immunother (2008) 57:601–609  605
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(2=0.519, P = 0.471), indicating that irradiation had no
eVect on HLA class I expression in these patients.
HLA class I negative cells and microsatellite instability
It has been described that a majority of MSI colorectal
tumors do not express HLA class I, while only a minority
of MSS tumors do not express HLA class I [8, 16]. There-
fore, HLA class I negative rectal tumors are the most at risk
to be MSI tumors. To evaluate the numbers of sporadic
MSI tumors in our study, HCA2 or HC10 negative tumors
were analyzed for the expression of PMS2 and MLH1.
PMS2 and MLH1 are mismatch repairs proteins that are
most frequently absent in MSI sporadic tumors [6]. Of the
HLA class I negative tumors only 1 out of 11 tumors did
not express PMS2 and MLH1. In the tumor group negative
for only 1 of the 2 HLA class I markers, 2 of 81 tumors dis-
played no PMS2 and MLH1 staining. These results indicate
that HLA class I down-regulation is not associated with
MSI in rectal cancer and are in accordance with the previ-
ous Wndings that only a very small minority of rectal tumors
are MSI [4, 25].
HLA class I expression and clinicopathological parameters
The relationship between HLA class I expression and
patient/tumor characteristics was assessed (Table 3). The
HLA class I expression levels were distributed equally in
non-irradiated and irradiated patients with regard to most
clinical and pathological parameters. Three signiWcant
diVerences were observed. For the non-irradiated patients,
signiWcantly more men appeared in the HLA class I low-
expression group (P = 0.03). The group of irradiated
tumors with HLA class I low expression contained signiW-
cantly more stage III and IV tumors (P = 0.01) and also
more patients with a tumor-positive circumferential resection
margin (P = 0.02) when compared with tumors with high
HLA class I expression.
Expression of HLA class I and clinical prognosis
Because radiotherapy might inXuence local tumor recur-
rences [15], irradiated and non-irradiated tumors were ana-
lyzed separately in order to evaluate the impact of HLA
class I expression on tumor recurrence and patient survival.
The HLA class I expression was not related with distant or
local recurrence rates. The patients with low expression
of HLA class I had a worse overall survival and disease-
free survival when compared to patients with HLA class I
high expression, irrespective of treatment (Fig. 2; overall
survival: P = 0.008 and P = 0.01; disease free survival:
P =0 . 0 1 ,   P = 0.006 in irradiated and non-irradiated
patients, respectively). Irradiated patients with low HLA
class I expression also had a worse cancer-speciWc survival
(P = 0.003). For non-irradiated patients, HLA class I
expression had no signiWcant eVect on cancer-speciWc sur-
vival (Fig. 2). All results of univariate analysis are shown
in Table 4. Univariate analysis showed a better outcome for
overall survival and disease-free survival in patients with
high HLA class I expression.
Multivariate analysis
Multivariate analysis was performed to identify factors
with independent prognostic signiWcance and to calculate
hazard ratios (HR). Analyses included TNM, circumfer-
ential margin, randomization for preoperative radiother-
apy and HLA class I expression (low vs. high HLA class I
positive tumor cells) (Table 5). Advanced pathological
(TNM) stage and tumor-positive circumferential resection
margins retained their strength as independent prognostic
factors in these survival analyses. HLA class I expression
Table 2 Expression of HLA class I in rectal cancer using HCA2 and HC10 antibodies
Expression of results of HCA2 and HC10 staining in a cross table for numbers (N) of irradiated and non-irradiated patients; expression of HCA2
and HC10 in more than 50% of the tumor cells (high) versus expression in less than 50% of the tumor cells (low) is shown. A signiWcant correlation
was noted between HCA2 and HC10 staining for both irradiated (2 = 53.947, P < 0.001) and non-irradiated patients (2 = 61.257, P <0 . 0 0 1 ) .  T h e
right side of the table displays HLA class I expression estimated on HCA2 and HC10 expression. A total of 406 (85%) irradiated and 445 (84%)
non-irradiated tumors exhibited expression of at least one of the two markers showing >50% positive staining of all tumor cells. A total of 70 (15%)
irradiated and 88 (16%) non-irradiated tumors showed reduced numbers (·50%) of HLA class I positive tumor cells. The number of patients in
the group of the HLA class I high expression group and the HLA class I low expression group was equally distributed between irradiated and non-
irradiated tumors (2 = 0.519, P =0 . 4 7 1 )
HCA2 HC10 HLA class I
High (N) Low + absence (N) N (%)
Irradiated High (N) 270 37 406 (85%)
Low + absence (N) 99 70 70 (15%)
Non-irradiated High (N) 277 32 445 (84%)
Low + absence (N) 136 87 87 (16%)606 Cancer Immunol Immunother (2008) 57:601–609
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showed independent prognostic value for overall survival
and disease-free survival (HR: 1.3, P = 0.042 and HR:
1.4, P = 0.006, respectively), but not for cancer-speciWc
survival.
Discussion
We showed that rectal cancer patients from the HLA class I
low expression group had an independent worse overall and
disease-free survival when compared to patients from the
HLA class I high-expression group. These data imply that
the expression of HLA class I in tumor cells predicts sur-
vival for rectal cancer patients. Although signiWcant better
cancer-speciWc survival for irradiated patients with high
HLA class I was found in univariate analysis, the predictive
value was lost in multivariate analysis. This observation
can be explained by the fact that the group with low HLA
class I signiWcantly included more stage III/IV and more
patients with a positive circumferential margin as compared
to the group of patients with high expression of HLA class
I. Also no predictive value of HLA class I expression was
found with regard to recurrence-free survival of these
patients. Therefore, we have no indications that support the
notion that better survival of high HLA class I expression is
due to the better antigen presenting function of these tumor
cells, as has been suggested [18, 35].
In our study, no diVerence was found between irradi-
ated and non-irradiated patients for HLA class I expres-
sion in tumor cells. It has been described that -irradiation
induces enhanced peptide production and surface expres-
sion of MHC class I in a colorectal mouse tumor cell line
[26]. The fact that we could not Wnd more HLA class I
expression in irradiated tumors than in non-irradiated
tumors indicates that radiotherapy does not induce HLA
class I expression in vivo. Immunohistochemistry, how-
ever, is less suitable to measure subtle expression changes.
Therefore, additional research is required to determine the
impact of radiotherapy on expression levels of HLA class
I in human tumors.
In our study, more tumors showed HLA class I down-
regulation after immunohistochemical staining using HCA2
than using HC10. This diVerence might be due to diVerences
in reactivity spectrum of both antibodies (see Materials
and methods) or to the fact that HLA alleles are diVerently
aVected in colorectal cancer. If the latter is the case, our
results suggest that HLA A alleles preferentially show down-
regulation in rectal cancer.
Previous reports evaluated HLA class I expression in
mixed patient populations of colon and rectal cancer
Table 3 Clinicopathological characteristics of irradiated and non-irradiated patients with high or low numbers of HLA class I positive tumor cells 
Number (N) of patients with expression of total HLA class I expression in more than 50% of the tumor cells (high) and expression in less than 50%
of the tumor cells (low)
* Statistical signiWcant P values are in bold
Non-irradiated patients Irradiated patients
High N = 445 Low N =8 7 P value High N =4 0 6 L o w   N =7 0 P value
Gender
Male (%) 63 75 0.03 65 66 0.90
Age
Median years 65 68 0.32 65 65 0.99
TNM stage (%)
I3 1 2 4 0 . 5 2 3 3 2 4 0.01
II 27 30 30 21
III 36 38 32 40
IV 5 8 5 14
Circumferential margin
Negative (%) 83 77 0.28 86 74 0.02
Distant from anal verge (%)
¸10 cm 28 33 0.17 27 32 0.30
5–10 cm 41 31 46 36
< 5 cm 31 36 27 32
Operation type (%)
Low anterior resection 66 61 0.77 65 66 0.89
Abdomino-perineal resection 29 33 29 30
Hartmann 5 6 6 4Cancer Immunol Immunother (2008) 57:601–609  607
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patients [18, 35]. Watson et al. also found in a large group
of colorectal cancer patients that patients with low expres-
sion of HLA class I had a poor prognosis [35]. However, in
contrast to our results, both studies described a substantial
population of patients with tumors showing absence of HLA
class I. In addition, they described that absence of HLA
class I was associated with better prognosis as compared to
tumors expressing reduced numbers of HLA class I positive
tumor cells. A relatively low number (1.1%) of HLA class I
negative tumors was observed in our cohort of rectal cancer
patients only. These patients showed no survival advantage
when compared to patients with reduced numbers of HLA
class I positive tumor cells. There are several explanations
for the discrepancy in the number of HLA class I negative
tumors between the study of Watson et al. and ours, like
diVerent deWnition of HLA class I expression, diVerences in
Fig. 2 Examples of Kaplan–
Meier curves showing overall 
survival and cancer speciWc 
survival for irradiated and non-
irradiated patients (a–d). 
Kaplan–Meier curves for overall 
survival (a, b) and cancer 
speciWc survival (c, d); curves 
show prognosis for non-irradiated 
(a, c) and irradiated patients 
(b, d) for HLA class I expression 
in more than 50% of the tumor 
cells (high) versus expression in 
less than 50% of the tumor cells 
(low). P value is based on 
univariate log rank analyses
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Table 4 Both irradiated and non-irradiated patients with high expression of HLA class I have a better overall, and disease free survival
Survival and recurrence rates indicated in percentages after 5-years of follow-up for non-irradiated and irradiated patients for HLA class I expres-
sion in more than 50% of the tumor cells (high) versus expression in less than 50% of the tumor cells (low). P value is based on univariate log rank
analyses for overall survival, disease free survival, cancer speciWc survival, local recurrence and distant recurrence
* Statistical signiWcant P values are in bold
Non-irradiated patients Irradiated patients
High (%) Low (%) P value High (%) Low (%) P value
Overall survival 65.5 58.5 0.012 67.5 51.3 0.008
Disease free survival 62.2 53.5 0.015 62.2 48.3 0.006
Cancer speciWc survival 74.3 71.4 0.41 80.1 61.8 0.003
Local recurrence 8.9 13.7 0.22 4.7 3.2 0.72
Distant recurrence 26.7 28.7 0.88 24.7 29.3 0.34608 Cancer Immunol Immunother (2008) 57:601–609
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staining techniques, diVerent patient cohort and number of
MSI tumors.
We showed that tumors that do not stain HC10 can stain
positive for HCA2 and thus are still able to present anti-
gens. Therefore, an explanation for the diVerences with the
results of Watson et al. is that we used strict criteria to clas-
sify tumors as HLA class I absent (deWned as both HCA2
and HC10 negative) as compared to Watson et al. (deWned
as negative for HC10 or negative for 2 m instead of nega-
tive for both). Another important explanation is that we
examined HLA class I expression in a relative more homo-
geneous population of patients with a rectal tumor, while
the other cohorts are more heterogeneous, consisting of
both colon and rectal cancer. Although combining results
from colon and rectum is generally accepted when predict-
ing prognosis, this might inXuence results [14].
In colon cancer patients, approximately 50% of all
proximal colon tumors show MSI, whereas almost all dis-
tal colon and rectal cancers are MSS tumors [24, 30].
Loss of HLA class I has been described in at least 60% of
all sporadic right-sided MSI colorectal tumors but in only
17% of MSS right-sided colon tumors loss of HLA class I
is found [8, 16]. In our cohort, only 1 out of 11 HLA neg-
ative tumors and 2 out of 81 tumors negative for HCA2
or HC10 did not express MLH1 and PMS2 and were thus
likely MSI tumors. This indicates that rectal cancers are
mainly MSS tumors, as has previously been described
[4, 14, 25]. Of the multiple mechanisms that have been
shown to underlie defects in HLA class I expression in
colorectal cancer (mutations in the individual HLA class
I genes, mutations in 2m  [ 16], and defects in compo-
nents of the HLA class I-associated antigen processing
machinery (APM) [2, 16]), only the Wrst will result in
allele-speciWc aberrancies while the other aVect total
HLA class I expression and may result in total absence in
a tumor cell.
These observations imply that a population of colorectal
tumors with total absence of HLA class I probably contains
a disproportionate large number of MSI tumors when com-
pared to colorectal tumors expressing HLA class I. In addi-
tion, MSI colorectal tumors have a better prognosis when
compared to MSS colorectal tumors [12,  24]. Therefore,
HLA class I negative tumors are more likely to be MSI
tumors with a diVerent clinical behavior as compared to
MSS colorectal tumors. It is likely that MSI inXuences
prognostic results when considering HLA class I expres-
sion in colorectal tumors.
Our results show that HLA class I expression in rectal
cancer aVects the patient’s prognosis. We hypothesize that
both oncogenic pathway and HLA class I expression dictate
clinical tumor progression. We suggest that in future prog-
nostic studies, analyzing expression of HLA class I or other
biomarkers in colorectal cancer, the impact of MSI should
be considered.
Table 5 Multivariate analysis conWrms independent better overall, and disease free survival for rectal cancer patients with high expression of HLA
class I
Multivariate analysis for cancer speciWc, overall and disease free survival was performed to identify factors with independent prognostic signiW-
cance and to calculate hazard ratios (HR) with 95% conWdence intervals (CI) shown in parentheses. HLA class I expression in more than 50% of
the tumor cells (high) versus expression in less than 50% of the tumor cells (low), total mesorectal excision (TME), Radiotherapy (RT); circumfer-
ential margin (CRM); P value is based on Cox’ regression analyses
* Statistical signiWcant P values and HR are in bold
Overall survival Disease free survival Cancer speciWc survival
HR (95% CI)  P value HR (95% CI)  P value HR (95% CI)  P value
HLA
High 10 . 0 4 2 1 0 . 0 0 6 10 . 6 5 3
Low 1.3 (1.0–1.6) 1.4 (1.1–1.8) 1.1 (0.8–1.5)
Randomization
TME 1 0.632 1 0.214 1 0.282
TME + RT 1 (0.8–1.2) 0.9 (0.7–1.1) 1.1 (0.9–1.5)
TNM
I 11 1
II 2.2 (1.7–3.0) <0.001 2.1 (1.6–2.8) <0.001 3.5 (2.0–6.1) <0.001
III 3.1 (2.4–4.1) <0.001 3.1 (2.3–4.0) <0.001 9.0 (5.4–14.9) <0.001
IV 11.8 (8.1–17.1) <0.001 – – 50.3 (28.5–89.1) <0.001
CRM
Negative 1 <0.001 1 <0.001 1 <0.001
Positive 1.3 (1.1–1.5) 1.8 (1.4–2.2) 1.3 (1.1–1.5)Cancer Immunol Immunother (2008) 57:601–609  609
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